| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Evan Peterson, Rosaria Forlan. Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. vol 25. issue 6. 2019-04-01. PMID:28696131. |
partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole. |
2019-04-01 |
2023-08-13 |
Not clear |
| N Simon, J-M Azori. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact]. L'Encephale. vol 44. issue 6. 2019-03-25. PMID:30466778. |
[aripiprazole as dopamine partial agonist model: basic concepts and clinical impact]. |
2019-03-25 |
2023-08-13 |
Not clear |
| Chia-Hsiang Chan, Hung-Yu Chan, Yen-Ching Che. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study. International clinical psychopharmacology. vol 33. issue 3. 2019-02-25. PMID:29324468. |
aripiprazole is a second-generation antipsychotics, acting as a partial dopamine d2 receptor agonist. |
2019-02-25 |
2023-08-13 |
Not clear |
| Sulgi Yoo, Mi-Yeon Kim, Jae Youl Ch. Syk and Src-targeted anti-inflammatory activity of aripiprazole, an atypical antipsychotic. Biochemical pharmacology. vol 148. 2018-12-17. PMID:29241811. |
aripiprazole (arp) is a partial agonist of dopamine d2 receptors that is commonly prescribed to treat schizophrenia and bipolar disorder. |
2018-12-17 |
2023-08-13 |
Not clear |
| Sangho Shin, Seoyoung Kim, Seongho Seo, Jae Sung Lee, Oliver D Howes, Euitae Kim, Jun Soo Kwo. The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [ Translational psychiatry. vol 8. issue 1. 2018-12-11. PMID:29686254. |
this study aims to investigate aripiprazole's effect on working memory by determining the correlation between dopamine d2/3 (d2/3) receptor occupancy and working memory of patients with schizophrenia. |
2018-12-11 |
2023-08-13 |
Not clear |
| Kohei Takahashi, Osamu Nakagawasai, Wataru Nemoto, Takayo Odaira, Wakana Sakuma, Koichi Tan-N. Antidepressant-like effect of aripiprazole via 5-HT Journal of pharmacological sciences. vol 137. issue 3. 2018-10-19. PMID:30061071. |
we have reported that aripiprazole (ari) ameliorates the behavioral hyper-responsivity to dopamine agonists and memory deficits in obx mice; however, it is unclear whether ari affects obx-induced depressive-like behavior. |
2018-10-19 |
2023-08-13 |
mouse |
| Roger Hudson, Yan Zhou, Francesco Ler. The combination of escitalopram and aripiprazole: Investigation of psychomotor effects in rats. Journal of psychopharmacology (Oxford, England). vol 31. issue 12. 2018-07-11. PMID:29069975. |
pre-clinical and clinical evidence suggests that the antidepressant efficacy of the selective serotonin reuptake inhibitor escitalopram can be enhanced by the dopamine and serotonin partial agonist aripiprazole. |
2018-07-11 |
2023-08-13 |
rat |
| Thomas Beresford, Jennifer Buchanan, Elizabeth Brie Thumm, Chad Emrick, David Weitzenkamp, Patrick J Rona. Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence. Journal of clinical psychopharmacology. vol 37. issue 6. 2018-06-14. PMID:28984746. |
traditional neuroleptics block dopamine receptors, whereas aripiprazole modulates dopamine activity as an agonist/antagonist. |
2018-06-14 |
2023-08-13 |
Not clear |
| Edith J Liemburg, Frank van Es, Henderikus Knegtering, André Alema. Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study. Progress in neuro-psychopharmacology & biological psychiatry. vol 79. issue Pt B. 2018-05-29. PMID:28558941. |
whereas most antipsychotics may decrease prefrontal activation, the partial dopamine d2-receptor agonist aripiprazole is hypothesized to improve prefrontal function. |
2018-05-29 |
2023-08-13 |
Not clear |
| Lyang Huh, Bong Ju Le. [Efficacy of low-Dose Aripiprazole to Treat Clozapine-Associated Tardive Dystonia in a Patient with Schizophrenia]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 28. issue 3. 2018-05-25. PMID:28936820. |
aripiprazole is a dopamine d2 receptor partial agonist that exhibits partial agonistic activity against serotonin-1a (5-ht1a) receptors and full antagonistic activity against 5-ht2a receptors. |
2018-05-25 |
2023-08-13 |
Not clear |
| Heather B Madsen, Isabel C Zbukvic, Sophia J Luikinga, Andrew J Lawrence, Jee Hyun Ki. Extinction of conditioned cues attenuates incubation of cocaine craving in adolescent and adult rats. Neurobiology of learning and memory. vol 143. 2018-05-24. PMID:27614140. |
rats were injected with aripiprazole, a dopamine 2 receptor (d2r)-like partial agonist, or vehicle, 30min prior to cue extinction. |
2018-05-24 |
2023-08-13 |
rat |
| Christoph U Correll, Eva Kohegyi, Cathy Zhao, Ross A Baker, Robert McQuade, Phyllis M Salzman, Raymond Sanchez, Margaretta Nyilas, William Carso. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. Journal of the American Academy of Child and Adolescent Psychiatry. vol 56. issue 9. 2018-05-03. PMID:28838583. |
to evaluate the efficacy, safety, and tolerability of aripiprazole, a dopamine d |
2018-05-03 |
2023-08-13 |
Not clear |
| Austen B Casey, Clinton E Cana. Classics in Chemical Neuroscience: Aripiprazole. ACS chemical neuroscience. vol 8. issue 6. 2018-05-01. PMID:28368577. |
aripiprazole was the first antipsychotic developed to possess agonist properties at dopamine d |
2018-05-01 |
2023-08-13 |
Not clear |
| Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Karina Hansen, Dieter Nabe. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY. International clinical psychopharmacology. vol 32. issue 3. 2017-12-18. PMID:28252452. |
in qualify, a randomized study, aripiprazole once-monthly 400 mg (aom 400), a dopamine d2 receptor partial agonist, showed noninferiority and subsequent superiority versus paliperidone palmitate (pp), a dopamine d2 receptor antagonist, on the heinrichs-carpenter quality-of-life scale (qls) in patients with schizophrenia aged 18-60 years. |
2017-12-18 |
2023-08-13 |
Not clear |
| P Seema. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational psychiatry. vol 6. issue 10. 2017-12-04. PMID:27754480. |
it was found that cannabidiol inhibited the binding of radio-domperidone with dissociation constants of 11 nm at dopamine d2high receptors and 2800 nm at dopamine d2low receptors, in the same biphasic manner as a dopamine partial agonist antipsychotic drug such as aripiprazole. |
2017-12-04 |
2023-08-13 |
rat |
| Mustafa Küçükköse, Bürge Kabukçu Başa. [Acute Dystonia due to Aripiprazole Use in Two Children with Autism Spectrum Disorder in the First Five Years of Life]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 28. issue 1. 2017-08-28. PMID:28291301. |
aripiprazole is a partial agonist for the dopamine d2, serotonin 5-ht1a receptors, and an antagonist for 5ht2a receptors. |
2017-08-28 |
2023-08-13 |
Not clear |
| Eric Promme. Aripiprazole. The American journal of hospice & palliative care. vol 34. issue 2. 2017-07-14. PMID:26589880. |
aripiprazole is a third-generation antipsychotic with a dopamine receptor-binding profile distinct from other second-generation antipsychotics. |
2017-07-14 |
2023-08-13 |
Not clear |
| Eric Promme. Aripiprazole. The American journal of hospice & palliative care. vol 34. issue 2. 2017-07-14. PMID:26589880. |
aripiprazole acts as partial agonist at dopamine d |
2017-07-14 |
2023-08-13 |
Not clear |
| Guido K W Frank, Megan E Shott, Jennifer O Hagman, Marissa A Schiel, Marisa C DeGuzman, Brogan Ross. The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa. The International journal of eating disorders. vol 50. issue 4. 2017-07-07. PMID:28334444. |
the partial dopamine d2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa. |
2017-07-07 |
2023-08-13 |
Not clear |
| Xin Chen, John D McCorvy, Matthew G Fischer, Kyle V Butler, Yudao Shen, Bryan L Roth, Jian Ji. Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists. Journal of medicinal chemistry. vol 59. issue 23. 2017-06-15. PMID:27805392. |
we previously discovered first-in-class β-arrestin-biased agonists of dopamine d2 receptor (d2r) by extensively exploring multiple regions of aripiprazole, a balanced d2r agonist. |
2017-06-15 |
2023-08-13 |
Not clear |